Mallinckrodt has received reports of thromboembolic events associated with the use of the THERAKOS CELLEX Photopheresis System in the treatment of Graft versus Host Disease (GvHD). Patients with GvHD have an increased risk of thromboembolic events. The Caution Statement will be updated in the device Operator's Manual section, titled "Anticoagulation."